NCT04925687View on ClinicalTrials.gov

Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

Intravitreal autologous CD34+ cells

Autologous CD34+ cells harvested from bone marrow injected intravitreal

Trial Locations (1)

95817

University of California Davis, Sacramento

All Listed Sponsors
collaborator

Cures Within Reach

OTHER

collaborator

The Retina Society

UNKNOWN

lead

University of California, Davis

OTHER